Pet Cancer Therapeutics Market Size By Medicine Type (Chemotherapy Drugs, Vaccines), By Species (Dogs, Cats), By Cancer Type (Lymphoma, Mast Cell Cancer, Melanoma, Mammary and Squamous Cell Cancer), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025
Published Date: Mar 2019 | Report ID: GMI2017 | Authors: Sumant Ugalmugle
Industry Trends
Pet Cancer Therapeutics Market size was valued at USD 178.0 million in 2018 and is expected to witness approximately 10.8% CAGR from 2019 to 2025.
Get more details on this report - Request Free Sample PDF
Increasing trend of pet adoption such as dogs and cats owing to improved economic status of people will drive market size. Furthermore, rising prevalence of pet cancer and growing pet healthcare expenditure will stimulate industry growth.
Growing R&D initiatives to treat pet cancer will result into launch of novel products in the market over the forecast years. Industry players with robust product pipelines will continue to expand the market share with their innovative treatments.
The adverse effects of pet cancer drugs and lack of awareness about pet diseases among the pet owners will restrain business growth. High cost of pet cancer therapeutics will further hamper pet health in most developing as well as under-developed countries across the world.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2018 | Market Size in 2018: | 178 Million (USD) |
| Historical Data for: | 2014 to 2018 | Forecast Period: | 2019 to 2025 |
| Forecast Period 2019 to 2025 CAGR: | 10.8% | 2025 Value Projection: | 359.4 Million (USD) |
| Pages: | 120 | Tables, Charts & Figures: | 149 |
| Geographies covered (13): | U.S., Canada, Germany, UK, France, Italy, Spain, Japan, China, India, Australia, Brazil, Mexico | ||
| Segments covered: | Medicine Type, Species, Cancer Type and Region | ||
| Companies covered (10): | AB Science, Aratana Therapeutics, Canfel Therapeutics, Karyopharms Therapeutics, Merial Inc., Oasmia Pharmaceuticals AB, Regeneus, VetiVax, VetDC, Inc., Zoetis | ||
| Growth Drivers: |
|
||
| Pitfalls & Challenges: |
|
||
Request 15% Free Customization on this Report
Pet Cancer Therapeutics Market, By Medicine Type
Get more details on this report - Request Free Sample PDF
Chemotherapy drugs held the highest pet cancer therapeutics market share in 2018 and is expected to reach USD 211.0 million by 2025. Launch of new drugs for treatment of various cancers is anticipated to augment pet cancer therapeutics market share over the forecast years.
Pet cancer vaccines are comparatively newer and lesser practiced medicine than chemotherapy; therefore, holds a relatively small market share. With more number of vaccines in pipeline the pet cancer therapeutics market share should at healthy CAGR of 13.4% over the forecast years.
Pet Cancer Therapeutics Market, By Species
Dog cancer therapeutics market held largest revenue share in 2018 and is forecasted to reach USD 343.9 million by 2025. Early inception and high number of marketed drugs and vaccines for dog cancer treatment will boost market growth. Over 80% of pet cancer pipeline drugs contains medication for dogs; therefore, dog cancer therapeutics market will grow with higher CAGR as compared to cats.
Low number of medicines for treatment of cancer in cats have resulted into a very low market share. However, with specialized cat cancer medicine in pipeline, the market is likely to grow at a considerable CAGR of 9.8% over the forecast years.
Pet Cancer Therapeutics Market, By Cancer Type
Pet cancer therapeutics for lymphoma market is expected to expand at 19.1% CAGR across the forecast timeframe. Lymphoma is the most common pet cancer type, especially in dogs. However, until the year 2016, there had been hardly any medicine available for dog cancer treatment. Many companies have robust drugs pipeline for lymphoma treatment which is anticipated to boost industry growth over the forecast years.
Mast cell cancer held largest pet cancer therapeutics market share and is expected to reach USD 137.5 million by 2025. High growth rate is due to availability of drugs for its treatment. However, shifting focus of companies from mast cell cancer to other cancer treatments may slower down the mast cell cancer therapeutics market growth over the forecast timeframe.
Pet cancer therapeutics Market, By Region
Get more details on this report - Request Free Sample PDF
North America market accounted for more than 80% of the overall revenue share in 2018, owing to the regional presence of several established players. Early product adoption and advances in product development to address different pet cancers will drive industry growth.
India market is projected to witness over 12.7% CAGR over the forecast timeframe. Increasing awareness, availability of various pet caner medicine and increasing pet healthcare spending will drive the business growth.
Competitive Market Share
Some of the notable industry players include Zoetis, Merial, Aratana Therapeutics, AB Science, Vetivax, VetDC, Regeneus and Karyopharms Verdinexor. The established players hold significant market share and have their presence in several regions. Moderate level of competition is seen among the companies as they have targeted different pet cancers with their unique product offering. New product launches, strategic mergers and acquisition, and geographic expansion are some of the strategies practiced to manifest competitive advantage.
Pet cancer therapeutics Industry Background
The Pet cancer therapeutics sector is a relatively new compared to other pet healthcare sectors. Over the past 8 years, it has evolved rapidly in terms of product development and coverage of broad pool of cancers that affect pet animals. The industry has been consistently dominated by established big pharmaceuticals companies. However, new specialised pet cancer therapeutics companies have been entering into the market in recent times.
Buy Now
Need a Discount? Get in touch with us for special pricing
Request DiscountConnect with our sales team
- Phone: 1-302-846-7766
- Toll Free: 1-888-689-0688
- Email: [email protected]
- Chat With Us: Click here to start
GMIPulse Subscription
An interactive business analytics platform; designed to assist clients in accessing and analyzing market data on real-time basis.
Start Your Free TrialBenefits of Association
Data Coverage & Quality
GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.
Client Trust & Security
GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.
Customer Service
Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.